JPH07502517A - 精神病の治療のためのアリールインドールの使用 - Google Patents

精神病の治療のためのアリールインドールの使用

Info

Publication number
JPH07502517A
JPH07502517A JP5511365A JP51136593A JPH07502517A JP H07502517 A JPH07502517 A JP H07502517A JP 5511365 A JP5511365 A JP 5511365A JP 51136593 A JP51136593 A JP 51136593A JP H07502517 A JPH07502517 A JP H07502517A
Authority
JP
Japan
Prior art keywords
substituted
alkyl
hydrogen
group
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5511365A
Other languages
English (en)
Japanese (ja)
Inventor
プレゴール・イエンス・クリスチアン
スカルスフェルト・トールベン
Original Assignee
ハー・ルンドベック・アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハー・ルンドベック・アクティーゼルスカブ filed Critical ハー・ルンドベック・アクティーゼルスカブ
Publication of JPH07502517A publication Critical patent/JPH07502517A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP5511365A 1991-12-23 1992-12-21 精神病の治療のためのアリールインドールの使用 Pending JPH07502517A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK912065A DK206591D0 (da) 1991-12-23 1991-12-23 Behandling af psykoser
DK2065/91 1991-12-23
PCT/DK1992/000390 WO1993012790A1 (en) 1991-12-23 1992-12-21 Use of arylindole derivatives for the treatment of psychoses

Publications (1)

Publication Number Publication Date
JPH07502517A true JPH07502517A (ja) 1995-03-16

Family

ID=8109829

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5511365A Pending JPH07502517A (ja) 1991-12-23 1992-12-21 精神病の治療のためのアリールインドールの使用

Country Status (11)

Country Link
EP (1) EP0618799A1 (enrdf_load_stackoverflow)
JP (1) JPH07502517A (enrdf_load_stackoverflow)
AU (1) AU668537B2 (enrdf_load_stackoverflow)
CA (1) CA2126571A1 (enrdf_load_stackoverflow)
CZ (1) CZ153994A3 (enrdf_load_stackoverflow)
DK (1) DK206591D0 (enrdf_load_stackoverflow)
NO (1) NO942378L (enrdf_load_stackoverflow)
RU (1) RU94031165A (enrdf_load_stackoverflow)
SK (1) SK75794A3 (enrdf_load_stackoverflow)
WO (1) WO1993012790A1 (enrdf_load_stackoverflow)
ZA (1) ZA9210001B (enrdf_load_stackoverflow)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554030A (en) * 1994-06-30 1996-09-10 Minnesota Mining And Manufacturing Company Method for bonding non-amalgam restorative materials to dental surfaces
KR20000004966A (ko) * 1996-03-25 2000-01-25 피터 지. 스트링거 편두통 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
DK238190D0 (da) * 1990-10-03 1990-10-03 Lundbeck & Co As H Depotderivater
DK8492D0 (da) * 1992-01-23 1992-01-23 Lundbeck & Co As H Behandling af psykoser

Also Published As

Publication number Publication date
CZ153994A3 (en) 1995-06-14
RU94031165A (ru) 1996-06-20
CA2126571A1 (en) 1993-07-08
AU668537B2 (en) 1996-05-09
DK206591D0 (da) 1991-12-23
NO942378L (no) 1994-06-22
SK75794A3 (en) 1995-04-12
ZA9210001B (en) 1994-01-13
AU3345293A (en) 1993-07-28
NO942378D0 (enrdf_load_stackoverflow) 1994-06-22
EP0618799A1 (en) 1994-10-12
WO1993012790A1 (en) 1993-07-08

Similar Documents

Publication Publication Date Title
CA2014208C (en) Selective blocking of spontaneously-active dopamine neurones in ventral tegmental area
US5238945A (en) Method of treating psychoses
JPH05507731A (ja) 物質乱用障害の治療用医薬組成物
KR100469029B1 (ko) 세로토닌재흡수억제제의위장효과를극복하기위한5ht4수용체길항제의용도
HK1002825B (en) Use of sertindole for the treatment of schizophrenia
WO2007093624A2 (en) Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
CN109574993A (zh) 取代的嘧啶哌嗪化合物及其用途
BG63190B1 (bg) Използване на оптически чист (+) норцисаприд за лечение на емезис и смущения на централната нервна система
JP3245642B2 (ja) 物質濫用疾患治療剤
EP2716302A1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
CA2345406A1 (en) Analgesic
JPH02134368A (ja) 新規なピリジル‐およびピリミジル誘導体
JP2001511763A (ja) 尿失禁の治療のための５−ｈｔ▲下１ａ▼受容体アンタゴニストの使用
JPH03500641A (ja) 精神分裂症用薬剤
RO115725B1 (ro) Esteri ai acidului nicotinic, procedee de preparare, compozitie care ii contine, si metoda de tratament
JPH07502517A (ja) 精神病の治療のためのアリールインドールの使用
KR20070043965A (ko) Ｎｒ2ｂ 수용체 길항물질인 키뉴렌산 아미드 유도체
CN100354274C (zh) 神经变性疾病的预防和治疗药物
AU670063B2 (en) Use of 3-arylindole and 3-arylindazole derivatives for the treatment of psychoses
JPH06505021A (ja) ドラッグ及び物質の乱用による中毒の治療
JPH07509711A (ja) 新規なピリジル−およびピリミジルピペラジン誘導体
JP2000007568A (ja) 神経栄養因子様作用剤
WO2006034788A1 (en) Combinations of n-(indolecarbonyl-)piperazine derivatives and serotonin reuptake inhibitors